The sphingolipid rheostat: A potential target for improving pancreatic islet survival and function

Endocrine, Metabolic and Immune Disorders - Drug Targets

Volumn 11, Issue 4, 2011, Pages 262-272

  Jessup, Claire F ^a,d   Bonder, Claudine S ^a,b   Pitson, Stuart M ^a,b   Coates, P Toby H ^a,c,d  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b CENTRE FOR CANCER BIOLOGY   (Australia)

^c Australian Islet Transplant Consortium   (Australia)

^d ROYAL ADELAIDE HOSPITAL   (Australia)

Author keywords

Apoptosis; Diabetes; Fty720; Islet transplantation; Revascularization; Sphingolipid rheostat; Sphingosine kinase; Sphingosine 1 phosphate

Indexed keywords

ALPHA GLUCOSIDASE INHIBITOR; CALCIUM; CERAMIDE; CYCLOSPORIN; FINGOLIMOD; G PROTEIN COUPLED RECEPTOR; INSULIN DERIVATIVE; LX 2931; METFORMIN; MONOCLONAL ANTIBODY; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; RAPAMYCIN; SONEPCIZUMAB; SPHINGOLIPID; SPHINGOSINE 1 PHOSPHATE; SPHINGOSINE KINASE; TACROLIMUS; UNCLASSIFIED DRUG;

APOPTOSIS; CALCIUM MOBILIZATION; CELL SURVIVAL; CELL TYPE; CYTOSKELETON; DIABETOGENESIS; HEART RATE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MITOGENESIS; MULTIPLE SCLEROSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS FUNCTION; PANCREAS ISLET; PANCREAS ISLET BETA CELL; PANCREAS ISLET TRANSPLANTATION; REGULATORY MECHANISM; RETINA MACULA EDEMA; REVIEW; SECOND MESSENGER; SIDE EFFECT; SIGNAL TRANSDUCTION; STEM CELL; VASCULAR ENDOTHELIUM;

EID: 80055103133     PISSN: 18715303     EISSN: 18715303     Source Type: Journal    
DOI: 10.2174/187153011797881201     Document Type: Review

References (131)

1. Adeghate, E.; Schattner, P. and Dunn, E. (2006) An update on the etiology and epidemiology of diabetes mellitus. Ann. N. Y. Acad. Sci., 1084, 1-29.
2. Herman, W. H. (2011) The economics of diabetes prevention. Med. Clin. North Am., 95, 373-384.
3. Reynoso-Noveron, N.; Mehta, R.; Almeda-Valdes, P.; Rojas-Martinez, R.; Villalpando, S.; Hernandez-Avila, M. and Aguilar-Salinas, C. A. (2011) Estimated incidence of cardiovascular complications related to type 2 diabetes in Mexico using the UKPDS outcome model and a population-based survey. Cardiovasc. Diabetol., 10, 1.
4. Alejandro, R.; Barton, F. B.; Hering, B. J. and Wease, S. (2008) 2008 Update from the Collaborative Islet Transplant Registry. Transplantation, 86, 1783-1788.
5. Balamurugan, A. N.; Bottino, R.; Giannoukakis, N. and Smetanka, C. (2006) Prospective and challenges of islet transplantation for the therapy of autoimmune diabetes. Pancreas, 32, 231-243.
6. Mandala, S.; Hajdu, R.; Bergstrom, J.; Quackenbush, E.; Xie, J.; Milligan, J.; Thornton, R.; Shei, G. J.; Card, D.; Keohane, C.; Rosenbach, M.; Hale, J.; Lynch, C. L.; Rupprecht, K.; Parsons, W. and Rosen, H. (2002) Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists. Science, 296, 346-349.
7. von Herrath, M. and Nepom, G. T. (2009) Animal models of human type 1 diabetes. Nat. Immunol., 10, 129-132.
8. Wenzlau, J. M.; Juhl, K.; Yu, L.; Moua, O.; Sarkar, S. A.; Gottlieb, P.; Rewers, M.; Eisenbarth, G. S.; Jensen, J.; Davidson, H. W. and Hutton, J. C. (2007) The cation efflux transporter ZnT8 (Slc30A8) is a major autoantigen in human type 1 diabetes. Proc. Natl. Acad. Sci. USA, 104, 17040-17045.
9. Bluestone, J. A.; Herold, K. and Eisenbarth, G. (2010) Genetics, pathogenesis and clinical interventions in type 1 diabetes. Nature, 464, 1293-1300.
10. Pietropaolo, M.; Barinas-Mitchell, E. and Kuller, L. H. (2007) The heterogeneity of diabetes: unraveling a dispute: is systemic inflammation related to islet autoimmunity? Diabetes, 56, 1189-1197.
11. Donath, M. Y. and Shoelson, S. E. (2011) Type 2 diabetes as an inflammatory disease. Nat. Rev. Immunol., 11, 98-107.
12. Diabetes prevalence in Australia: an assessment of national data sources, in Diabetes series, Australian Institute of Health and Welfare, Canberra, 2009.
13. Houstis, N.; Rosen, E. D. and Lander, E. S. (2006) Reactive oxygen species have a causal role in multiple forms of insulin resistance. Nature, 440, 944-948.
14. Fox, T. E. and Kester, M. (2010) Therapeutic strategies for diabetes and complications: a role for sphingolipids? Adv. Exp. Med. Biol., 688, 206-216.
15. Samad, F.; Hester, K. D.; Yang, G.; Hannun, Y. A. and Bielawski, J. (2006) Altered adipose and plasma sphingolipid metabolism in obesity: a potential mechanism for cardiovascular and metabolic risk. Diabetes, 55, 2579-2587.
16. Holland, W. L.; Miller, R. A.; Wang, Z. V.; Sun, K.; Barth, B. M.; Bui, H. H.; Davis, K. E.; Bikman, B. T.; Halberg, N.; Rutkowski, J. M.; Wade, M. R.; Tenorio, V. M.; Kuo, M. S.; Brozinick, J. T.; Zhang, B. B.; Birnbaum, M. J.; Summers, S. A. and Scherer, P. E. (2011) Receptor-mediated activation of ceramidase activity initiates the pleiotropic actions of adiponectin. Nat. Med., 17, 55-63.
17. Jessup, C. F. C. (2010) 2010-2012: Strategic plan. Working to build a healthy Australia., Australian Government.
18. Fiorina, P.; Shapiro, A. M.; Ricordi, C. and Secchi, A. (2008) The clinical impact of islet transplantation. Am. J. Transplant., 8, 1990-1997.
19. Shapiro, A. M.; Ricordi, C.; Hering, B. J.; Auchincloss, H.; Lindblad, R.; Robertson, R. P.; Secchi, A.; Brendel, M. D.; Berney, T.; Brennan, D. C.; Cagliero, E.; Alejandro, R.; Ryan, E. A.; DiMercurio, B.; Morel, P.; Polonsky, K. S.; Reems, J. A.; Bretzel, R. G.; Bertuzzi, F.; Froud, T.; Kandaswamy, R.; Sutherland, D. E.; Eisenbarth, G.; Segal, M.; Preiksaitis, J.; Korbutt, G. S.; Barton, F. B.; Viviano, L.; Seyfert-Margolis, V.; Bluestone, J. and Lakey, J. R. (2006) International trial of the Edmonton protocol for islet transplantation. N. Engl. J. Med., 355, 1318-1330.
20. Shapiro, A. M.; Lakey, J. R.; Ryan, E. A.; Korbutt, G. S.; Toth, E.; Warnock, G. L.; Kneteman, N. M. and Rajotte, R. V. (2000) Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N. Engl. J. Med., 343, 230-238.
21. Thompson, D. M.; Meloche, M.; Ao, Z.; Paty, B.; Keown, P.; Shapiro, R. J.; Ho, S.; Worsley, D.; Fung, M.; Meneilly, G.; Begg, I.; Al Mehthel, M.; Kondi, J.; Harris, C.; Fensom, B.; Kozak, S. E.; Tong, S. O.; Trinh, M. and Warnock, G. L. (2011) Reduced Progression of Diabetic Microvascular Complications With Islet Cell Transplantation Compared With Intensive Medical Therapy. Transplantation, 91, 373-378.
22. Emamaullee, J. A. and Shapiro, A. M. (2006) Interventional strategies to prevent beta-cell apoptosis in islet transplantation. Diabetes, 55, 1907-1914.
23. Jansson, L. and Carlsson, P. O. (2002) Graft vascular function after transplantation of pancreatic islets. Diabetologia, 45, 749-763.
24. Chen, C.; Moreno, R.; Samikannu, B.; Bretzel, R. G.; Schmitz, M. L. and Linn, T. (2011) Improved Intraportal Islet Transplantation Outcome by Systemic IKK-beta Inhibition: NF-kappaB Activity in Pancreatic Islets Depends on Oxygen Availability. Am. J. Transplant., 11, 215-224.
25. Cheng, K.; Ho, K.; Stokes, R.; Scott, C.; Lau, S. M.; Hawthorne, W. J.; O'Connell, P. J.; Loudovaris, T.; Kay, T. W.; Kulkarni, R. N.; Okada, T.; Wang, X. L.; Yim, S. H.; Shah, Y.; Grey, S. T.; Biankin, A. V.; Kench, J. G.; Laybutt, D. R.; Gonzalez, F. J.; Kahn, C. R. and Gunton, J. E. (2010) Hypoxia-inducible factor-1alpha regulates beta cell function in mouse and human islets. J. Clin. Invest., 120, 2171-2183.
26. Johnson, M. C.; Wang, B. and Tisch, R. (2011) Genetic vaccination for reestablishing T cell tolerance in type 1 diabetes. Hum. Vaccin., 7, 27-36.
27. Skyler, J. S. and Ricordi, C. (2011) Stopping type 1 diabetes: attempts to prevent or cure type 1 diabetes in man. Diabetes, 60, 1-8.
28. Boettler, T. and Herrath, M. V. (2011) Type 1 diabetes vaccine development: Animal models vs. humans. Hum. Vaccin., 7, 19-26.
29. Moller, D. E. (2001) New drug targets for type 2 diabetes and the metabolic syndrome. Nature, 414, 821-827.
30. Balamurugan, A. N.; Breite, A. G.; Anazawa, T.; Loganathan, G.; Wilhelm, J. J.; Papas, K. K.; Dwulet, F. E.; McCarthy, R. C. and Hering, B. J. (2010) Successful human islet isolation and transplantation indicating the importance of class 1 collagenase and collagen degradation activity assay. Transplantation, 89, 954-961.
31. Hughes, A.; Jessup, C.; Drogemuller, C.; Mohanasundaram, D.; Milner, C.; Rojas, D.; Russ, G. R. and Coates, P. T. (2010) Gene therapy to improve pancreatic islet transplantation for Type 1 diabetes mellitus. Curr. Diabetes Rev., 6, 274-284.
32. Nanji, S. A. and Shapiro, A. M. (2004) Islet transplantation in patients with diabetes mellitus: choice of immunosuppression. BioDrugs, 18, 315-328.
33. Pappu, R.; Schwab, S. R.; Cornelissen, I.; Pereira, J. P.; Regard, J. B.; Xu, Y.; Camerer, E.; Zheng, Y. W.; Huang, Y.; Cyster, J. G. and Coughlin, S. R. (2007) Promotion of lymphocyte egress into blood and lymph by distinct sources of sphingosine-1-phosphate. Science, 316, 295-298.
34. Cuvillier, O.; Pirianov, G.; Kleuser, B.; Vanek, P. G.; Coso, O. A.; Gutkind, S. and Spiegel, S. (1996) Suppression of ceramide-mediated programmed cell death by sphingosine-1-phosphate. Nature, 381, 800-803.
35. Pitson, S. M. (2011) Regulation of sphingosine kinase and sphingolipid signaling. Trends Biochem. Sci., 36, 97-107.
36. Maceyka, M.; Milstien, S. and Spiegel, S. (2009) Sphingosine-1-phosphate: the Swiss army knife of sphingolipid signaling. J. Lipid. Res., 50 Suppl, S272-276.
37. Hait, N. C.; Oskeritzian, C. A.; Paugh, S. W.; Milstien, S. and Spiegel, S. (2006) Sphingosine kinases, sphingosine 1-phosphate, apoptosis and diseases. Biochim. Biophys. Acta., 1758, 2016-2026.
38. Pyne, N. J. and Pyne, S. (2010) Sphingosine 1-phosphate and cancer. Nat. Rev. Cancer, 10, 489-503.
39. Olivera, A.; Kohama, T.; Edsall, L.; Nava, V.; Cuvillier, O.; Poulton, S. and Spiegel, S. (1999) Sphingosine kinase expression increases intracellular sphingosine-1-phosphate and promotes cell growth and survival. J. Cell Biol., 147, 545-558.
40. Maceyka, M.; Sankala, H.; Hait, N. C.; le Stunff, H.; Liu, H.; Toman, R.; Collier, C.; Zhang, M.; Satin, L. S.; Merrill, A.H.; Milstien, S. and Spiegel, S. (2005) SphK1 and SphK2, sphingosine kinase isoenzymes with opposing functions in sphingolipid metabolism. J. Biol. Chem., 280, 37118-37129.
41. Hofmann, L. P.; Ren, S.; Schwalm, S.; Pfeilschifter, J. and Huwiler, A. (2008) Sphingosine kinase 1 and 2 regulate the capacity of mesangial cells to resist apoptotic stimuli in an opposing manner. Biol. Chem., 389, 1399-1407.
42. Pitson, S. M.; D'Andrea, R. J.; Vandeleur, L.; Moretti, P. A.; Xia, P.; Gamble, J. R.; Vadas, M. A. and Wattenberg, B. W. (2000) Human sphingosine kinase: purification, molecular cloning and characterization of the native and recombinant enzymes. Biochem. J., 350 Pt 2, 429-441.
43. Pitson, S. M.; Moretti, P. A.; Zebol, J. R.; Lynn, H. E.; Xia, P.; Vadas, M. A. and Wattenberg, B. W. (2003) Activation of sphingosine kinase 1 by ERK1/2-mediated phosphorylation. EMBO J., 22, 5491-5500.
44. Hait, N. C.; Bellamy, A.; Milstien, S.; Kordula, T. and Spiegel, S. (2007) Sphingosine kinase type 2 activation by ERK-mediated phosphorylation. J. Biol. Chem., 282, 12058-12065.
45. Liu, H.; Sugiura, M.; Nava, V. E.; Edsall, L. C.; Kono, K.; Poulton, S.; Milstien, S.; Kohama, T. and Spiegel, S. (2000) Molecular cloning and functional characterization of a novel mammalian sphingosine kinase type 2 isoform. J. Biol. Chem., 275, 19513-19520.
46. Allende, M. L.; Sasaki, T.; Kawai, H.; Olivera, A.; Mi, Y.; van Echten-Deckert, G.; Hajdu, R.; Rosenbach, M.; Keohane, C. A.; Mandala, S.; Spiegel, S. and Proia, R. L. (2004) Mice deficient in sphingosine kinase 1 are rendered lymphopenic by FTY720. J. Biol. Chem., 279, 52487-52492.
47. Kharel, Y.; Lee, S.; Snyder, A. H.; Sheasley-O'neill, S. L.; Morris, M. A.; Setiady, Y.; Zhu, R.; Zigler, M. A.; Burcin, T. L.; Ley, K.; Tung, K. S.; Engelhard, V. H.; Macdonald, T. L.; Pearson-White, S. and Lynch, K. R. (2005) Sphingosine kinase 2 is required for modulation of lymphocyte traffic by FTY720. J. Biol. Chem., 280, 36865-36872.
48. Mizugishi, K.; Yamashita, T.; Olivera, A.; Miller, G. F.; Spiegel, S. and Proia, R. L. (2005) Essential role for sphingosine kinases in neural and vascular development. Mol. Cell Biol., 25, 11113-11121.
49. Hait, N. C.; Allegood, J.; Maceyka, M.; Strub, G. M.; Harikumar, K. B.; Singh, S. K.; Luo, C.; Marmorstein, R.; Kordula, T.; Milstien, S. and Spiegel, S. (2009) Regulation of histone acetylation in the nucleus by sphingosine-1-phosphate. Science, 325, 1254-1257.
50. Alvarez, S. E.; Harikumar, K. B.; Hait, N. C.; Allegood, J.; Strub, G. M.; Kim, E. Y.; Maceyka, M.; Jiang, H.; Luo, C.; Kordula, T.; Milstien, S. and Spiegel, S. (2010) Sphingosine-1-phosphate is a missing cofactor for the E3 ubiquitin ligase TRAF2. Nature, 465, 1084-1088.
51. Bonder, C. S.; Sun, W. Y.; Matthews, T.; Cassano, C.; Li, X.; Ramshaw, H. S.; Pitson, S. M.; Lopez, A. F.; Coates, P. T.; Proia, R. L.; Vadas, M. A. and Gamble, J. R. (2009) Sphingosine kinase regulates the rate of endothelial progenitor cell differentiation. Blood, 113, 2108-2117.
52. Gamble, J. R.; Sun, W. Y.; Li, X.; Hahn, C. N.; Pitson, S. M.; Vadas, M. A. and Bonder, C. S. (2009) Sphingosine kinase-1 associates with integrin {alpha}V{beta}3 to mediate endothelial cell survival. Am. J. Pathol., 175, 2217-2225.
53. Sun, W. Y.; Pitson, S. M. and Bonder, C. S. (2010) Tumor necrosis factor-induced neutrophil adhesion occurs via sphingosine kinase-1-dependent activation of endothelial {alpha}5{beta}1 integrin. Am. J. Pathol., 177, 436-446.
54. Kim, R. H.; Takabe, K.; Milstien, S. and Spiegel, S. (2009) Export and functions of sphingosine-1-phosphate. Biochim. Biophys. Acta., 1791, 692-696.
55. Rivera, J.; Proia, R. L. and Olivera, A. (2008) The alliance of sphingosine-1-phosphate and its receptors in immunity. Nat. Rev. Immunol., 8, 753-763.
56. Rosen, H.; Gonzalez-Cabrera, P. J.; Sanna, M. G. and Brown, S. (2009) Sphingosine 1-phosphate receptor signaling. Annu. Rev. Biochem., 78, 743-768.
57. Fyrst, H. and Saba, J. D. (2010) An update on sphingosine-1-phosphate and other sphingolipid mediators. Nat. Chem. Biol., 6, 489-497.
58. Takabe, K.; Kim, R. H.; Allegood, J. C.; Mitra, P.; Ramachandran, S.; Nagahashi, M.; Harikumar, K. B.; Hait, N. C.; Milstien, S. and Spiegel, S. (2010) Estradiol induces export of sphingosine 1-phosphate from breast cancer cells via ABCC1 and ABCG2. J. Biol. Chem., 285, 10477-10486.
59. Yatomi, Y.; Yamamura, S.; Ruan, F. and Igarashi, Y. (1997) Sphingosine 1-phosphate induces platelet activation through an extracellular action and shares a platelet surface receptor with lysophosphatidic acid. J. Biol. Chem., 272, 5291-5297.
60. Aoki, S.; Osada, M.; Kaneko, M.; Ozaki, Y. and Yatomi, Y. (2007) Fluid shear stress enhances the sphingosine 1-phosphate responses in cell-cell interactions between platelets and endothelial cells. Biochem. Biophys. Res. Commun., 358, 1054-1057.
61. Kluk, M. J. and Hla, T. (2002) Signaling of sphingosine-1-phosphate via the S1P/EDG-family of G-protein-coupled receptors. Biochim. Biophys. Acta., 1582, 72-80.
62. Olivera, A.; Mizugishi, K.; Tikhonova, A.; Ciaccia, L.; Odom, S.; Proia, R. L. and Rivera, J. (2007) The sphingosine kinase-sphingosine-1-phosphate axis is a determinant of mast cell function and anaphylaxis. Immunity, 26, 287-297.
63. Chun, J.; Hla, T.; Lynch, K. R.; Spiegel, S. and Moolenaar, W. H. (2010) International Union of Basic and Clinical Pharmacology. LXXVIII. Lysophospholipid receptor nomenclature. Pharmacol. Rev., 62, 579-587.
64. Meacci, E.; Becciolini, L.; Nuti, F.; Donati, C.; Cencetti, F.; Farnararo, M. and Bruni, P. (2002) A role for calcium in sphingosine 1-phosphate-induced phospholipase D activity in C2C12 myoblasts. FEBS Lett., 521, 200-204.
65. Meacci, E.; Cencetti, F.; Formigli, L.; Squecco, R.; Donati, C.; Tiribilli, B.; Quercioli, F.; Zecchi Orlandini, S.; Francini, F. and Bruni, P. (2002) Sphingosine 1-phosphate evokes calcium signals in C2C12 myoblasts via Edg3 and Edg5 receptors. Biochem. J., 362, 349-357.
66. Graeler, M. and Goetzl, E. J. (2002) Activation-regulated expression and chemotactic function of sphingosine 1-phosphate receptors in mouse splenic T cells. FASEB J., 16, 1874-1878.
67. Jin, Y.; Knudsen, E.; Wang, L.; Bryceson, Y.; Damaj, B.; Gessani, S. and Maghazachi, A. A. (2003) Sphingosine 1-phosphate is a novel inhibitor of T-cell proliferation. Blood, 101, 4909-4915.
68. Van Brocklyn, J. R.; Graler, M. H.; Bernhardt, G.; Hobson, J. P.; Lipp, M. and Spiegel, S. (2000) Sphingosine-1-phosphate is a ligand for the G protein-coupled receptor EDG-6. Blood, 95, 2624-2629.
69. Liu, Y.; Wada, R.; Yamashita, T.; Mi, Y.; Deng, C. X.; Hobson, J. P.; Rosenfeldt, H. M.; Nava, V. E.; Chae, S. S.; Lee, M. J.; Liu, C. H.; Hla, T.; Spiegel, S. and Proia, R. L. (2000) Edg-1, the G protein-coupled receptor for sphingosine-1-phosphate, is essential for vascular maturation. J. Clin. Invest., 106, 951-961.
70. Kluk, M. J. and Hla, T. (2001) Role of the sphingosine 1-phosphate receptor EDG-1 in vascular smooth muscle cell proliferation and migration. Circ. Res., 89, 496-502.
71. Wang, F.; Nohara, K.; Olivera, A.; Thompson, E. W. and Spiegel, S. (1999) Involvement of focal adhesion kinase in inhibition of motility of human breast cancer cells by sphingosine 1-phosphate. Exp. Cell Res., 247, 17-28.
72. Rosen, H.; Sanna, M. G.; Cahalan, S. M. and Gonzalez-Cabrera, P. J. (2007) Tipping the gatekeeper: S1P regulation of endothelial barrier function. Trends Immunol., 28, 102-107.
73. Matloubian, M.; Lo, C. G.; Cinamon, G.; Lesneski, M. J.; Xu, Y.; Brinkmann, V.; Allende, M. L.; Proia, R. L. and Cyster, J. G. (2004) Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature, 427, 355-360.
74. Walzer, T.; Chiossone, L.; Chaix, J.; Calver, A.; Carozzo, C.; Garrigue-Antar, L.; Jacques, Y.; Baratin, M.; Tomasello, E. and Vivier, E. (2007) Natural killer cell trafficking in vivo requires a dedicated sphingosine 1-phosphate receptor. Nat. Immunol., 8, 1337-1344.
75. Cinamon, G.; Matloubian, M.; Lesneski, M. J.; Xu, Y.; Low, C.; Lu, T.; Proia, R. L. and Cyster, J. G. (2004) Sphingosine 1-phosphate receptor 1 promotes B cell localization in the splenic marginal zone. Nat. Immunol., 5, 713-720.
76. Brinkmann, V.; Billich, A.; Baumruker, T.; Heining, P.; Schmouder, R.; Francis, G.; Aradhye, S. and Burtin, P. (2010) Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis. Nat. Rev. Drug Discov., 9, 883-897.
77. Fujita, T.; Inoue, K.; Yamamoto, S.; Ikumoto, T.; Sasaki, S.; Toyama, R.; Chiba, K.; Hoshino, Y. and Okumoto, T. (1994) Fungal metabolites. Part 11. A potent immunosuppressive activity found in Isaria sinclairii metabolite. J. Antibiot. (Tokyo)., 47, 208-215.
78. Zemann, B.; Kinzel, B.; Muller, M.; Reuschel, R.; Mechtcheriakova, D.; Urtz, N.; Bornancin, F.; Baumruker, T. and Billich, A. (2006) Sphingosine kinase type 2 is essential for lymphopenia induced by the immunomodulatory drug FTY720. Blood, 107, 1454-1458.
79. Brinkmann, V.; Davis, M. D.; Heise, C. E.; Albert, R.; Cottens, S.; Hof, R.; Bruns, C.; Prieschl, E.; Baumruker, T.; Hiestand, P.; Foster, C. A.; Zollinger, M. and Lynch, K. R. (2002) The immune modulator FTY720 targets sphingosine 1-phosphate receptors. J. Biol. Chem., 277, 21453-21457.
80. Graler, M. H. and Goetzl, E. J. (2004) The immunosuppressant FTY720 down-regulates sphingosine 1-phosphate G-protein-coupled receptors. FASEB J., 18, 551-553.
81. Oo, M. L.; Thangada, S.; Wu, M. T.; Liu, C. H.; Macdonald, T. L.; Lynch, K. R.; Lin, C. Y. and Hla, T. (2007) Immunosuppressive and anti-angiogenic sphingosine 1-phosphate receptor-1 agonists induce ubiquitinylation and proteasomal degradation of the receptor. J. Biol. Chem., 282, 9082-9089.
82. Pham, T. H.; Okada, T.; Matloubian, M.; Lo, C. G. and Cyster, J. G. (2008) S1P1 receptor signaling overrides retention mediated by G alpha i-coupled receptors to promote T cell egress. Immunity, 28, 122-133.
83. Lan, Y. Y.; De Creus, A.; Colvin, B. L.; Abe, M.; Brinkmann, V.; Coates, P. T. and Thomson, A. W. (2005) The sphingosine-1-phosphate receptor agonist FTY720 modulates dendritic cell trafficking in vivo. Am. J. Transplant., 5, 2649-2659.
84. Neviani, P.; Santhanam, R.; Oaks, J. J.; Eiring, A. M.; Notari, M.; Blaser, B. W.; Liu, S.; Trotta, R.; Muthusamy, N.; Gambacorti-Passerini, C.; Druker, B. J.; Cortes, J.; Marcucci, G.; Chen, C. S.; Verrills, N. M.; Roy, D. C.; Caligiuri, M. A.; Bloomfield, C. D.; Byrd, J. C. and Perrotti, D. (2007) FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia. J. Clin. Invest., 117, 2408-2421.
85. Don, A. S.; Martinez-Lamenca, C.; Webb, W. R.; Proia, R. L.; Roberts, E. and Rosen, H. (2007) Essential requirement for sphingosine kinase 2 in a sphingolipid apoptosis pathway activated by FTY720 analogues. J. Biol. Chem., 282, 15833-15842.
86. Bandhuvula, P.; Tam, Y. Y.; Oskouian, B. and Saba, J. D. (2005) The immune modulator FTY720 inhibits sphingosine-1-phosphate lyase activity. J. Biol. Chem., 280, 33697-33700.
87. Berdyshev, E. V.; Gorshkova, I.; Skobeleva, A.; Bittman, R.; Lu, X.; Dudek, S. M.; Mirzapoiazova, T.; Garcia, J. G. and Natarajan, V. (2009) FTY720 inhibits ceramide synthases and up-regulates dihydrosphingosine 1-phosphate formation in human lung endothelial cells. J. Biol. Chem., 284, 5467-5477.
88. Tonelli, F.; Lim, K. G.; Loveridge, C.; Long, J.; Pitson, S. M.; Tigyi, G.; Bittman, R.; Pyne, S. and Pyne, N. J. (2010) FTY720 and (S)-FTY720 vinylphosphonate inhibit sphingosine kinase 1 and promote its proteasomal degradation in human pulmonary artery smooth muscle, breast cancer and androgen-independent prostate cancer cells. Cell Signal., 22, 1536-1542.
89. Woodcock, J. M.; Ma, Y.; Coolen, C.; Pham, D.; Jones, C.; Lopez, A. F. and Pitson, S. M. (2010) Sphingosine and FTY720 directly bind pro-survival 14-3-3 proteins to regulate their function. Cell Signal., 22, 1291-1299.
90. Payne, S. G.; Oskeritzian, C. A.; Griffiths, R.; Subramanian, P.; Barbour, S. E.; Chalfant, C. E.; Milstien, S. and Spiegel, S. (2007) The immunosuppressant drug FTY720 inhibits cytosolic phospholipase A2 independently of sphingosine-1-phosphate receptors. Blood, 109, 1077-1085.
91. Mulgaonkar, S.; Tedesco, H.; Oppenheimer, F.; Walker, R.; Kunzendorf, U.; Russ, G.; Knoflach, A.; Patel, Y. and Ferguson, R. (2006) FTY720/cyclosporine regimens in de novo renal transplantation: a 1-year dose-finding study. Am. J. Transplant., 6, 1848-1857.
92. Budde, K.; Schmouder, R. L.; Brunkhorst, R.; Nashan, B.; Lucker, P. W.; Mayer, T.; Choudhury, S.; Skerjanec, A.; Kraus, G. and Neumayer, H. H. (2002) First human trial of FTY720, a novel immunomodulator, in stable renal transplant patients. J. Am. Soc. Nephrol., 13, 1073-1083.
93. Salvadori, M.; Budde, K.; Charpentier, B.; Klempnauer, J.; Nashan, B.; Pallardo, L. M.; Eris, J.; Schena, F. P.; Eisenberger, U.; Rostaing, L.; Hmissi, A. and Aradhye, S. (2006) FTY720 versus MMF with cyclosporine in de novo renal transplantation: a 1-year, randomized controlled trial in Europe and Australasia. Am. J. Transplant., 6, 2912-2921.
94. Tedesco-Silva, H.; Pescovitz, M. D.; Cibrik, D.; Rees, M. A.; Mulgaonkar, S.; Kahan, B. D.; Gugliuzza, K. K.; Rajagopalan, P. R.; Esmeraldo Rde, M.; Lord, H.; Salvadori, M. and Slade, J. M. (2006) Randomized controlled trial of FTY720 versus MMF in de novo renal transplantation. Transplantation, 82, 1689-1697.
95. Kappos, L.; Radue, E. W.; O'Connor, P.; Polman, C.; Hohlfeld, R.; Calabresi, P.; Selmaj, K.; Agoropoulou, C.; Leyk, M.; Zhang-Auberson, L. and Burtin, P. (2010) A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N. Engl. J. Med., 362, 387-401.
96. Cohen, J. A.; Barkhof, F.; Comi, G.; Hartung, H. P.; Khatri, B. O.; Montalban, X.; Pelletier, J.; Capra, R.; Gallo, P.; Izquierdo, G.; Tiel-Wilck, K.; de Vera, A.; Jin, J.; Stites, T.; Wu, S.; Aradhye, S. and Kappos, L. (2010) Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N. Engl. J. Med., 362, 402-415.
97. Fu, F.; Hu, S.; Deleo, J.; Li, S.; Hopf, C.; Hoover, J.; Wang, S.; Brinkmann, V.; Lake, P.; and Shi, V. C. (2002) Long-term islet graft survival in streptozotocin- and autoimmune-induced diabetes models by immunosuppressive and potential insulinotropic agent FTY720. Transplantation, 73, 1425-1430.
98. Truong, W.; Emamaullee, J. A.; Merani, S.; Anderson, C. C. and James Shapiro, A. M. (2007) Human islet function is not impaired by the sphingosine-1-phosphate receptor modulator FTY720. Am. J. Transplant., 7, 2031-2038.
99. Liu, L.; Wang, C.; He, X.; Shang, W.; Bi, Y. and Wang, D. (2007) Long-term effect of FTY720 on lymphocyte count and islet allograft survival in mice. Microsurgery, 27, 300-304.
100. Maeda, A.; Goto, M.; Zhang, J.; Bennet, W.; Groth, C. G.; Korsgren, O. and Wennberg, L. (2003) Immunosuppression with FTY720 and cyclosporine A inhibits rejection of adult porcine islet xenografts in rats. Transplantation, 75, 1409-1414.
101. Wijkstrom, M.; Kenyon, N. S.; Kirchhof, N.; Kenyon, N. M.; Mullon, C.; Lake, P.; Cottens, S.; Ricordi, C. and Hering, B. J. (2004) Islet allograft survival in nonhuman primates immunosuppressed with basiliximab, RAD, and FTY720. Transplantation, 77, 827-835.
102. Hering, B. J.; Wijkstrom, M.; Graham, M. L.; Hardstedt, M.; Aasheim, T. C.; Jie, T.; Ansite, J. D.; Nakano, M.; Cheng, J.; Li, W.; Moran, K.; Christians, U.; Finnegan, C.; Mills, C. D.; Sutherland, D. E.; Bansal-Pakala, P.; Murtaugh, M. P.; Kirchhof, N. and Schuurman, H. J. (2006) Prolonged diabetes reversal after intraportal xenotransplantation of wild-type porcine islets in immunosuppressed nonhuman primates. Nat. Med., 12, 301-303.
103. Goto, M.; Maeda, A.; Elfman, L.; Suling, K. M.; Wood, J. C.; Patience, C.; Groth, C. G.; and Wennberg, L. (2004) No transmission of porcine endogenous retrovirus after transplantation of adult porcine islets into diabetic nude mice and immunosuppressed rats. Xenotransplantation, 11, 340-346.
104. Honkanen, J.; Nieminen, J. K.; Gao, R.; Luopajarvi, K.; Salo, H. M.; Ilonen, J.; Knip, M.; Otonkoski, T. and Vaarala, O. (2010) IL-17 immunity in human type 1 diabetes. J. Immunol., 185, 1959-1967.
105. Mehling, M.; Lindberg, R.; Raulf, F.; Kuhle, J.; Hess, C.; Kappos, L. and Brinkmann, V. (2010) Th17 central memory T cells are reduced by FTY720 in patients with multiple sclerosis. Neurology, 75, 403-410.
106. Pitman, M. R. and Pitson, S. M. (2010) Inhibitors of the sphingosine kinase pathway as potential therapeutics. Curr. Cancer Drug Targets, 10, 354-367.
107. Xie, B.; Shen, J.; Dong, A.; Rashid, A.; Stoller, G. and Campochiaro, P. A. (2009) Blockade of sphingosine-1-phosphate reduces macrophage influx and retinal and choroidal neovascularization. J. Cell Physiol., 218, 192-198.
108. Bagdanoff, J. T.; Donoviel, M. S.; Nouraldeen, A.; Carlsen, M.; Jessop, T. C.; Tarver, J.; Aleem, S.; Dong, L.; Zhang, H.; Boteju, L.; Hazelwood, J.; Yan, J.; Bednarz, M.; Layek, S.; Owusu, I. B.; Gopinathan, S.; Moran, L.; Lai, Z.; Kramer, J.; Kimball, S. D.; Yalamanchili, P.; Heydorn, W. E.; Frazier, K. S.; Brooks, B.; Brown, P.; Wilson, A.; Sonnenburg, W. K.; Main, A.; Carson, K. G.; Oravecz, T. and Augeri, D. J. (2010) Inhibition of sphingosine 1-phosphate lyase for the treatment of rheumatoid arthritis: discovery of (E)-1-(4-((1R,2S,3R)-1,2,3,4-tetrahydroxybutyl)-1H-imidazol-2-yl)ethanone oxime (LX2931) and (1R,2S,3R)-1-(2-(isoxazol-3-yl)-1H-imidazol-4-yl)butane-1,2,3,4-tetraol (LX2932). J. Med. Chem., 53, 8650-8662.
109. Fox, T. E.; Bewley, M. C.; Unrath, K. A.; Pedersen, M. M.; Anderson, R. E.; Jung, D. Y.; Jefferson, L. S.; Kim, J. K.; Bronson, S. K.; Flanagan, J. M. and Kester, M. (2011) Circulating sphingolipid biomarkers in models of type 1 diabetes. J. Lipid Res., 52, 509-517.
110. Mastrandrea, L. D.; Sessanna, S. M. and Laychock, S. G. (2005) Sphingosine kinase activity and sphingosine-1 phosphate production in rat pancreatic islets and INS-1 cells: response to cytokines. Diabetes, 54, 1429-1436.
111. Mastrandrea, L. D.; Sessanna, S. M.; del Toro, A. and Laychock, S. G. (2010) ATP-independent glucose stimulation of sphingosine kinase in rat pancreatic islets. J. Lipid Res., 51, 2171-2180
112. Laychock, S. G.; Tian, Y. and Sessanna, S. M. (2003) Endothelial differentiation gene receptors in pancreatic islets and INS-1 cells. Diabetes, 52, 1986-1993.
113. Edsbagge, J.; Johansson, J. K.; Esni, F.; Luo, Y.; Radice, G. L.; and Semb, H. (2005) Vascular function and sphingosine-1-phosphate regulate development of the dorsal pancreatic mesenchyme. Development, 132, 1085-1092.
114. Ma, M. M.; Chen, J. L.; Wang, G. G.; Wang, H.; Lu, Y.; Li, J. F.; Yi, J.; Yuan, Y. J.; Zhang, Q. W.; Mi, J.; Wang, L.; Duan, H. F. and Wu, C. T. (2007) Sphingosine kinase 1 participates in insulin signalling and regulates glucose metabolism and homeostasis in KK/Ay diabetic mice. Diabetologia, 50, 891-900.
115. Bernal-Mizrachi, E.; Fatrai, S.; Johnson, J. D.; Ohsugi, M.; Otani, K.; Han, Z.; Polonsky, K. S. and Permutt, M. A. (2004) Defective insulin secretion and increased susceptibility to experimental diabetes are induced by reduced Akt activity in pancreatic islet beta cells. J. Clin. Invest., 114, 928-936.
116. Limaye, V.; Li, X.; Hahn, C.; Xia, P.; Berndt, M. C.; Vadas, M. A. and Gamble, J. R. (2005) Sphingosine kinase-1 enhances endothelial cell survival through a PECAM-1-dependent activation of PI-3K/Akt and regulation of Bcl-2 family members. Blood, 105, 3169-3177.
117. Laychock, S. G.; Sessanna, S. M.; Lin, M. H. and Mastrandrea, L. D. (2006) Sphingosine 1-phosphate affects cytokine-induced apoptosis in rat pancreatic islet beta-cells. Endocrinology, 147, 4705-4712.
118. Imasawa, T.; Koike, K.; Ishii, I.; Chun, J. and Yatomi, Y. (2010) Blockade of sphingosine 1-phosphate receptor 2 signaling attenuates streptozotocin-induced apoptosis of pancreatic beta-cells. Biochem. Biophys. Res. Commun., 392, 207-211.
119. Limaye, V.; Vadas, M. A.; Pitson, S. M. and Gamble, J. R. (2009) The effects of markedly raised intracellular sphingosine kinase-1 activity in endothelial cells. Cell. Mol. Biol. Lett., 14, 411-423.
120. Johansson, A.; Lau, J.; Sandberg, M.; Borg, L. A.; Magnusson, P. U. and Carlsson, P. O. (2009) Endothelial cell signalling supports pancreatic beta cell function in the rat. Diabetologia, 52, 2385-2394.
121. Watada, H. (2010) Role of VEGF-A in pancreatic beta cells. Endocr. J., 57, 185-191.
122. Igarashi, J.; Bernier, S. G. and Michel, T. (2001) Sphingosine 1-phosphate and activation of endothelial nitric-oxide synthase. differential regulation of Akt and MAP kinase pathways by EDG and bradykinin receptors in vascular endothelial cells. J. Biol. Chem., 276, 12420-12426.
123. Spinas, G. A. (1999) The Dual Role of Nitric Oxide in Islet beta-Cells. News Physiol. Sci., 14, 49-54.
124. Contreras, J. L.; Smyth, C. A.; Eckstein, C.; Bilbao, G.; Thompson, J. A.; Young, C. J.; and Eckhoff, D. E. (2003) Peripheral mobilization of recipient bone marrow-derived endothelial progenitor cells enhances pancreatic islet revascularization and engraftment after intraportal transplantation. Surgery, 134, 390-398.
125. Mathews, V.; Hanson, P. T.; Ford, E.; Fujita, J.; Polonsky, K. S. and Graubert, T. A. (2004) Recruitment of bone marrow-derived endothelial cells to sites of pancreatic beta-cell injury. Diabetes, 53, 91-98.
126. Wang, L.; Xing, X. P.; Holmes, A.; Wadham, C.; Gamble, J. R.; Vadas, M. A. and Xia, P. (2005) Activation of the sphingosine kinase-signaling pathway by high glucose mediates the pro-inflammatory phenotype of endothelial cells. Circ. Res., 97, 891-899.
127. Popovic, J.; Kover, K. L. and Moore, W. V. (2004) The effect of immunomodulators on prevention of autoimmune diabetes is stage dependent: FTY720 prevents diabetes at three different stages in the diabetes-resistant biobreeding rat. Pediatr. Diabetes., 5, 3-9.
128. Jorns, A.; Rath, K. J.; Terbish, T.; Arndt, T.; Meyer, Z. V. A.; Wedekind, D.; Hedrich, H. J. and Lenzen, S. (2010) Diabetes prevention by immunomodulatory FTY720 treatment in the LEW. 1AR1-iddm rat despite immune cell activation. Endocrinology, 151, 3555-3565.
129. Yang, Z.; Chen, M.; Fialkow, L. B.; Ellett, J. D.; Wu, R.; Brinkmann, V.; Nadler, J. L. and Lynch, K. R. (2003) The immune modulator FYT720 prevents autoimmune diabetes in nonobese diabetic mice small star, filled. Clin. Immunol., 107, 30-35.
130. Maki, T.; Gottschalk, R.; Ogawa, N. and Monaco, A. P. (2005) Prevention and cure of autoimmune diabetes in nonobese diabetic mice by continuous administration of FTY720. Transplantation, 79, 1051-1055.
131. Penaranda, C.; Tang, Q.; Ruddle, N. H. and Bluestone, J. A. (2010) Prevention of diabetes by FTY720-mediated stabilization of peri-islet tertiary lymphoid organs. Diabetes, 59, 1461-1468.